divaleryl-amine | 33655-40-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: divaleryl-amine
• 英文别名: N-Valeryl-valeramid；Divaleramide；N-pentanoylpentanamide
• CAS: 33655-40-2
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.266
• InChiKey: UFUJLYBHJBLJKT-UHFFFAOYSA-N

物化性质

• 沸点：
  298.1±9.0 °C(Predicted)
• 密度：
  0.942±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  正戊酸 在 苯甲腈 、 iron(II) chloride 作用下， 反应 19.0h， 以85%的产率得到divaleryl-amine
  参考文献：
  名称：

  Vorob'eva, E. M.; Litvyak, I. G.; Sumarokova, T. N., Journal of general chemistry of the USSR, 1980, vol. 50, # 11, p. 2043 - 2048

  摘要：

  DOI：

文献信息

• PIPERIDINE DERIVATIVE
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20190040039A1

  公开（公告）日：2019-02-07

  The purpose of the present invention is to provide a compound having excellent antibacterial activity against mycobacterium tuberculosis , multidrug-resistant tuberculosis bacteria, and/or non-tuberculous acid-fast bacteria. A compound represented by formula [I]: (in the formula, each symbol is as described in the attached specification), or a salt thereof can be used to diagnose, prevent, and/or treat tuberculosis.

  本发明的目的是提供一种对结核分枝杆菌、多药耐药结核菌和/或非结核性抗酸杆菌具有优异抗菌活性的化合物。可以利用由化学式[I]表示的化合物（在该化学式中，每个符号如所附规范所述），或其盐来诊断、预防和/或治疗结核病。
• Acyclic imides. A general method of N-acylation of amides
  作者：K. Baburao、A. M. Costello、R. C. Petterson、G. E. Sander

  DOI：10.1039/j39680002779

  日期：——

  Many methods of monoacylation of primary amides were studied; one, the sulphuric acid-catalysed reaction of amides with anhydrides at 100°, was found to be very general. Several new acyclic imides were synthesised, including compounds as diverse as N-acetylvaleramide, N-valeryl-4-methylvaleramide, and 3α-acetoxy-N-acetyl-cholanamide. In two cases symmetrical imides related to the anhydride used were

  研究了许多伯酰胺单酰化的方法。第一，发现酰胺与酸酐在100°的硫酸催化反应非常普遍。几种新的无环酰亚胺合成，包括等不同的化合物Ñ -acetylvaleramide，Ñ -valeryl -4-甲基戊酰胺，和3α乙酰氧基ñ -乙酰基cholanamide。在两种情况下，与所用酸酐有关的对称酰亚胺被确定为混合酰亚胺合成中的次要副产物。
• [EN] HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION POUR LE TRAITEMENT DE LA TURBERCULOSE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2016031255A1

  公开（公告）日：2016-03-03

  It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.

  本发明的目的是提供一种具有优异的抗结核菌、多药耐药结核菌和/或非结核分枝杆菌抗菌活性的化合物。公开的是一种一般式（1）的化合物：其中每个符号如附表规定的那样定义，或其盐。
• The Reaction of Nitriles with Phosgene. V. Cyclization Reactions of<i>N</i>-(α-Chlorobenzylidene)carbamoyl Chloride
  作者：Shozo Yanagida、Masaaki Yokoe、Masataka Ohoka、Saburo Komori

  DOI：10.1246/bcsj.44.2182

  日期：1971.8

  N-(α-Chlorobenzylidene)carbamoyl chloride (1) reacts with hydrazine hydrate to give 3-phenyl-1,2,4-triazolone (2), with sodium azide in the presence of water to give 5-phenyltetrazole (3), and with aliphatic nitriles in the presence of hydrogen chloride to give 6-chloro-2-phenyl-5-substituted-4(3H)-pyrimidones (5) and 4,6-dichloro-2-phenyl-5-substituted pyrimidines (6). However, the reaction of 1 with trichloroacetonitrile

  N-(α-氯亚苄基)氨基甲酰氯(1)与水合肼反应生成3-苯基-1,2,4-三唑酮(2)，在水存在下与叠氮化钠反应生成5-苯基四唑(3)，并在氯化氢存在下与脂肪族腈反应得到 6-氯-2-苯基-5-取代-4(3H)-嘧啶酮 (5) 和 4,6-二氯-2-苯基-5-取代嘧啶 (6 ）。然而，1 与三氯乙腈或新戊腈在氯化氢存在下的反应没有得到预期的三嗪。
• Novel isoindole derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US20040053923A1

  公开（公告）日：2004-03-18

  This invention relates to compounds represented by the general formula [I] 1 wherein, R represents an azido group, etc., R 1 and R 2 are the same or different and represent hydrogen atoms, etc., R 3 and R 4 are the same or different and represent hydrogen atoms, etc., X 1 represents an oxygen atom, etc., X 2 represents an oxygen atom, etc., Y represents an oxygen atom, etc., and Z represents a condensed aryl group, etc., or a pharmaceutically acceptable salt thereof, preparation processes thereof, and an agent for treating diabetes, a prophylactic agent for chronic complications of diabetes or a drug against obesity, containing, as an effective ingredient, the compound or the pharmaceutically acceptable salt thereof.

  本发明涉及由一般式[I]1表示的化合物，其中，R代表叠氮基等，R1和R2相同或不同，代表氢原子等，R3和R4相同或不同，代表氢原子等，X1代表氧原子等，X2代表氧原子等，Y代表氧原子等，Z代表紧缩芳基基团等，或其药学上可接受的盐，其制备方法以及作为治疗糖尿病的药物、预防糖尿病慢性并发症的预防剂或抗肥胖药物的有效成分，包含该化合物或其药学上可接受的盐。